L
The Lancet
An independent, international weekly general medical journal founded in 1823.
Impact Factor: 168.9Visit Journal
The Lancet
Biomarker risk stratification with capsule sponge in the surveillance of Barrett's oesophagus: prospective evaluation of UK real-world implementation
2025-06-23
research
The Lancet
Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial
2025-06-23
research
The Lancet
Targeting challenging RDEB skin wounds with gene therapy
2025-06-23
research
The Lancet
Timing of anticoagulation after ischaemic stroke and atrial fibrillation: better swift than sorry
2025-06-23
research
The Lancet
A public health prescription for US carceral facilities
2025-06-23
research
The Lancet
Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST)
2025-06-23
research
The Lancet
Early-onset type 2 diabetes: the next major diabetes transition
2025-06-23
research
The Lancet
Understanding the drivers and consequences of early-onset type 2 diabetes
2025-06-23
research
The Lancet
Managing early-onset type 2 diabetes in the individual and at the population level
2025-06-23
research
The Lancet
Early-onset type 2 diabetes: no time for defeatism
2025-06-23
research
The Lancet
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial
2025-06-22
research
The Lancet
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial
2025-06-22
research
The Lancet
Future of once-weekly insulins in type 2 diabetes: efficacy and safety
2025-06-22
research
The Lancet
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
2025-06-20
research
The Lancet
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
2025-06-20
research
The Lancet
GLP-1 and amylin receptor multiagonism with amycretin for obesity management
2025-06-20
research
The Lancet
Leptospirosis deaths in children in the Amazon: syndemic inequities
2025-06-20
research
The Lancet
Cerebral palsy
2025-06-20
research
The Lancet
Clade IIb mpox outbreak in Sierra Leone
2025-06-20
research
The Lancet
Current treatment for symptomatic uterine fibroids: available evidence and therapeutic dilemmas
2025-06-19
research